Determination of optimal vitamin D3 dosing regimens in HIV-infected paediatric patients using a population pharmacokinetic approach.
Br J Clin Pharmacol. 2014 Nov;78(5):1113-21. doi: 10.1111/bcp.12433.
Foissac F1, Meyzer C, Frange P, Chappuy H, Benaboud S, Bouazza N, Friedlander G, Souberbielle JC, Urien S, Blanche S, Tréluyer JM.
1EA 3620, Sorbonne Paris Cité, Université Paris Descartes, Paris, France; Unité de Recherche Clinique Paris Centre, Assistance Publique Hôpitaux de Paris (APHP), Paris, France.
To investigate 25-hydroxycholecalciferol 25(OH)D population pharmacokinetics in children and adolescents, to establish factors that influence 25(OH)D pharmacokinetics and to assess different vitamin D3 dosing schemes to reach sufficient 25(OH)D concentrations (>30 ng ml(-1) ).
This monocentric prospective study included 91 young HIV-infected patients aged 3 to 24 years. Patients received a 100 000 IU vitamin D3 supplementation. A total of 171 25(OH)D concentrations were used to perform a population pharmacokinetic analysis.
At baseline 28% of patients had 25(OH)D concentrations below 10 ng ml(-1) , 69% between 10 and 30 ng ml(-1) and 3% above 30 ng ml(-1) . 25(OH)D pharmacokinetics were best described by a one compartment model with an additional production parameter reflecting the input from diet and sun exposure. The effects of skin phototype and bodyweight were significant on 25(OH)D production before any supplementation. The basal level was 27% lower in non-white skin phototype patients and was slightly decreased with bodyweight. No significant differences in 25(OH)D concentrations were related to antiretroviral drugs.
To obtain concentrations between 30 and 80 ng ml(-1) , patients with baseline concentrations between 10 and 30 ng ml(-1) should receive 100 000 IU per 3 months.
However, vitamin D deficient patients (<10 ng ml(-1) ) would need an intensive phase of 100 000 IU per 2 weeks (two times) followed 2 weeks later by a maintenance phase of 100 000 IU per 3 months.
Skin phototype and bodyweight had an influence on the basal production of 25(OH)D. According to 25(OH)D baseline concentrations, dosing schemes to reach sufficient concentrations are proposed.
© 2014 The British Pharmacological Society.
Items in both categories HIV and Intervention are listed here:
- HIV treatment augmented by high-dose vitamin D, daily or weekly – Dec 2021
- HIV therapy reduces Vitamin D levels, supplementation helps - Nov 2019
- HIV patients helped by monthly 120,000 IU of Vitamin D – RCT Oct 2017
- 200,000 IU restored levels in HIV children having low vitamin D - Nov 2014
- Vitamin D levels of HIV and non HIV equally restored with 50,000 IU twice a week - July 2015
- Treatment of HIV in youths helped by 7,000 IU of vitamin D – RCT July 2014
- Those with HIV who doubled their vitamin D levels reduced their chance of death by 47 percent – Oct 2013
- HIV – recommend 100,000 IU vitamin D monthly to get levels 30 ng – May 2013